Safety of Sofosbuvir and Ribavirin Combination Therapy in a Patient Who Developed Anemia due to Ribavirin

Interferon (IFN) and ribavirin (RBV) combination therapy was previously the standard of care for treatment of hepatitis C virus (HCV) genotype 2 infection. But, it often induced hemolytic anemia. In 2014, sofosbuvir (SOF) was approved for the treatment of chronic HCV genotype 2 in Japan. SOF/RBV the...

Descripción completa

Detalles Bibliográficos
Autores principales: Suii, Hirokazu, Ozeki, Itaru, Tatsumi, Ryoji, Yamaguchi, Masakatsu, Kimura, Mutsuumi, Arakawa, Tomohiro, Nakajima, Tomoaki, Kuwata, Yasuaki, Ohmura, Takumi, Hige, Shuhei, Karino, Yoshiyasu, Toyota, Joji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5742439/
https://www.ncbi.nlm.nih.gov/pubmed/29375917
http://dx.doi.org/10.1155/2017/8793895

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5742439/
https://www.ncbi.nlm.nih.gov/pubmed/29375917
http://dx.doi.org/10.1155/2017/8793895

Ejemplares similares